Masked Facial Recognition in Security Systems Using Transfer Learning.

The COVID-19 is a crisis of unprecedented magnitude, which has resulted in countless casualties and security troubles. In view of recent events of corona virus people are required to wear face masks to protect themselves from getting infected. As a result, a good portion of face (nose and mouth) is hidden by the mask and hence the facial recognition becomes difficult. Many organizations use facial recognition as a means of authentication. Researchers focus on developing rapid and efficient solutions to deal with the ongoing coronavirus pandemic by coming up with suggestions for handling the facial recognition problem. This research paper aims to identify the person, while the face is covered with a facial mask with only eyes and forehead being exposed. The first step involves marking the facial region. Next, using the data set, we will implement an object detection model YOLOv3 to identify unmasked and masked faces. The YOLO v3 object detection model is the best performing model with a detection time of 0.012 s, F1 score of 0.90 and mAP score of 0.92. Experimental results on Real-World Masked-Face-Data set show high recognition performance.

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.

OBJECTIVES: Following antiretroviral therapy failure, patients are often treated with a three-drug regimen that includes two nucleoside/tide reverse transcriptase inhibitors [N(t)RTIs]. An alternative two-drug nucleoside-sparing regimen may decrease the pill burden and drug toxicities associated with the use of N(t)RTIs. The Intelence aNd pRezista Once A Day Study (INROADS; NCT01199939) evaluated the nucleoside-sparing regimen of etravirine 400 mg with darunavir/ritonavir 800/100 mg once-daily in HIV-1-infected treatment-experienced subjects or treatment-naïve subjects with transmitted resistance. METHODS: In this exploratory phase 2b, single-arm, open-label, multicentre, 48-week study, the primary endpoint was the proportion of subjects who achieved HIV-1 RNA < 50 copies/mL at week 48 [confirmed virological response (CVR), non-virological failure (VF) censored]. Key secondary endpoints included assessments of changes from baseline to week 48 in viral load, immunological response, pharmacokinetics/pharmacodynamics, safety, tolerability, metabolic and bone markers and body fat. RESULTS: Forty-one of the 54 enrolled subjects completed the study. Adverse events (7%) and VF (7%) were the most common reasons for discontinuation. The week 48 CVR rate in the intent-to-treat (ITT) non-VF censored population was 89% (primary endpoint). Seven subjects experienced VF. Common adverse events were diarrhoea (15%), rash (15%) and upper respiratory tract infection (11%). Mild/moderate lipid elevations, minimal changes in limb fat distribution and bone mineral density and no clinically relevant changes in glucose metabolism were observed. CONCLUSIONS: Etravirine 400 mg and darunavir/ritonavir 800/100 mg as a two-drug once-daily regimen in treatment-experienced subjects or treatment-naïve subjects with transmitted resistance was virologically efficacious and well tolerated.

Genitourinary tuberculosis after renal transplantation: report of 3 cases and review.

Mycobacterium tuberculosis infection of the genitourinary tract is an uncommon disease in renal transplant recipients and presentation is atypical. Genitourinary tuberculosis is associated with graft rejection, and this diagnosis should be considered for renal transplant recipients with unexplained fever and constitutional symptoms.

Sterol effects on phospholipid biosynthesis in the yeast strain GL7.

Cells of the yeast sterol auxotroph GL7 were grown on either ergosterol or cholesterol to mid-logarithmic phase and total membrane fractions prepared. Activities of phospholipid biosynthetic enzymes in the two cell types were determined. The rates of phosphatidyl-ethanolamine-phosphatidyl-choline-N-methyl transferase and acyl-CoA-alpha-glycerol-3-phosphate transcylase were significantly greater in ergosterol-grown than in cholesterol-grown cells. These reactions were also inhibited by the polyene antibiotic filipin. By contrast the activities of long-chain fatty acyl-CoA synthetase, CTP-phosphatidate-cytidyl transferase, phosphatidylserine decarboxylase and of phosphatidylinositol synthetase were identical in the two (ergosterol and cholesterol) cultures and unaffected by filipin. The ergosterol effect on phosphatidyl-ethanolamine N-methyl transferase was greatest in cells harvested in early log phase, intermediate in the mid-log phase cells, and not significant in stationary phase cells.

Sterol control of the phosphatidylethanolamine-phosphatidylcholine conversion in the yeast mutant GL7.

The relatively slow growth rate of the yeast mutant GL7, a sterol auxotroph, on medium containing cholesterol is markedly accelerated by supplementation with small amounts of ergosterol. Under these conditions (sterol synergism) cellular phospholipid synthesis is enhanced. We now find that one of the ergosterol-stimulated processes is the methylation of phosphatidylethanolamine to phosphatidylcholine. This is shown by comparing methyltransferase activities of membrane preparations derived from cells grown on either ergosterol, cholesterol, or the synergistic sterol pair. Incorporation of 32P from [gamma-32P]ATP into the yeast membranes is rapid and greater when ergosterol-grown cells rather than cholesterol-grown cells are the source of membranes.

Sterol synergism in yeast.

Sterol synergism as previously observed [Dahl, C.E., Dahl, J.S. & Bloch, K. (1980) Biochemistry 19, 1462-1467] and defined as a greater-than-additive growth response to pairs of sterols by Mycoplasma capricolum [Dahl, J.S., Dahl, C.E. & Bloch, K. (1981) J. Biol. Chem. 256, 87-91] is now demonstrated in the yeast mutant GL7, which is auxotrophic for sterol and unsaturated fatty acid. Mutant cells growing poorly when provided with cholesterol and oleic acid respond to ergosterol supplements (ergosterol-to-cholesterol ratio, 1:3) by a pronounced increase in growth rates and cell yields. Stigmasterol also elicits a significant synergistic effect, and 7-dehydrocholesterol, a smaller one. Evidence for a metabolic role of ergosterol in yeast membranes is presented. Cells raised on a 1:3 mixture of ergosterol to cholesterol up to midlogarithmic phase subsequently incorporate [1-14C]oleic acid at significantly faster rates into phospholipids than do cells grown on cholesterol alone.

Mutagenicity of islandicin and chrysophanol in the Salmonella/microsome system.

Chrysophanol and islandicin, two anthraquinones which are structurally related to emodin, were found to be frame-shift mutagens for Salmonella typhimurium strain TA 1537 after metabolic activation.

Viral hepatitis: progress and problems.

The recognition of viral hepatitis has been facilitated by the use of serologic studies for types A, B, and non-A, non-B. The course is best determined by serum enzyme determinations, followed by clearance studies of bile acids or dyes once the serum enzymes return to normal. In patients with persisting clinical or biochemical abnormalities and those in which the nature of the disease is not known, liver biopsy should be done.